Chartwell's mission is dedicated to maximizing the quality of life and dignity of the patients and clients we serve. Our core values define our business culture where the contributions of every individual are recognized and rewarded in pursuit of a shared vision. Read more Our Care Team Pharmacy Pharmacists ensure that drug and dosing are appropriate to diagnosis/therapy, monitor patients' medication profile, alert to potential drug/food interactions, allergies and sensitivities as well as ongoing clinical monitoring.
Methotrexate is given weekly as an intramuscular injection of 15 to 25 mg. Side effects are rare and include leukopenia and hypersensitivity interstitial pneumonitis. Hepatic fibrosis is the most severe potential sequela of long-term therapy. Patients with concomitant alcohol abuse and/or morbid obesity are more likely to develop hepatic fibrosis and therefore should not be treated with methotrexate. It is prudent to obtain a baseline chest radiograph and to monitor complete blood count, liver function and renal function every two weeks until the patient is receiving oral therapy, and every one to three months thereafter. Before methotrexate therapy is initiated, the risks of treatment and the possible need for a liver biopsy should be discussed with the patient.
Ulcerative colitis and Crohn's disease: 300 mg IV at zero, two and six weeks and then every eight weeks thereafter.
Comments: Discontinue if no evidence of therapeutic benefit by Week 14.
Adult Ulcerative Colitis (UC):
Adults with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. This drug is used for inducing and maintaining clinical response or remission, improving endoscopic appearance of the mucosa, or achieving corticosteroid-free remission.
Adult Crohn's Disease(CD):
Adults with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. This drug is used for achieving clinical response or remission, or achieving corticosteroid-free remission.